Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

TerminatedOBSERVATIONAL
Enrollment

14

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

April 4, 2025

Conditions
Biliary Tract CancerCholangiocarcinomaGallbladder CancerIntrahepatic CholangiocarcinomaPerihilar CholangiocarcinomaExtrahepatic CholangiocarcinomaHilar CholangiocarcinomaDistal Bile Duct Cancer
Interventions
DIAGNOSTIC_TEST

Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring

All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection. All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.

Trial Locations (2)

60612

University of Illinois at Chicago, Chicago

98195

University of Washington, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Natera, Inc.

INDUSTRY

collaborator

SEngine Precision Medicine, Inc.

UNKNOWN

lead

University of Washington

OTHER

NCT04561453 - Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | Biotech Hunter | Biotech Hunter